CLINICAL TRIALS AND OBSERVATIONS Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials
نویسندگان
چکیده
1Inserm U728, Paris, France; Université Paris 7, U728, Paris, France; 2Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Service de Pathologie, Paris, France; 3Service de Cancérologie, CHU de Nice l’Archet, Clinique Universitaire des Spécialités Médicales, Nice, France; 4Service d’Hématologie adulte, Hôpital Saint Louis, Paris, France; 5Service d’Hématologie, Hôpital Robert Debré, Reims cedex, France; 6Institute for Pathology, University Clinic of Schleswig-Holstein (UK-SH), Lübeck, Germany; 7Department of Pathology, Vrije Universiteit Medical Center (VUMC), Amsterdam, The Netherlands; 8Service de Pathologie, Hôpital Ambroise Paré, Faculté de Médecine Boulogne cedex, France; 9Service d’Hématologie, Institut Paoli-Calmettes, Marseille, France; 10Service d’Hématologie, Université Catholique de Louvain, Mont Godinne, Yvoir, Belgium; 11Service d’Anatomie Pathologique, Hôpital Hôtel Dieu, Paris, France; 12Service d’Hématologie, Hôpital Henri Mondor, Créteil, France; 13Service d’Hématologie, Pierre Bénite, France; 14Inserm, U728, Paris, France; Université Paris 7, U728, Paris, France; AP-HP, Hôpital Saint-Louis, Service d’Hématologie, Paris, France; and 15Inserm U841, Créteil, France; Université Paris 12, Faculté de médecine, Créteil, France; AP-HP, Hôpital Henri Mondor, Département de Pathologie, Créteil, France
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n 267). Patients in complete remission (CR) or partial response of ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
The survival of patients with aggressive non-Hodgkin lymphoma (NHL) is increasing, but the incidence of secondary cancer and late toxicity is poorly defined for those treated with cyclophosphamidehydroxydaunomycin/doxorubicin-Oncovin-prednisone (CHOP)–like chemotherapy. From February 1984 to January 1998, 2837 patients with aggressive NHL received the control-arm chemotherapy adriamycin-cycloph...
متن کاملCLINICAL TRIALS AND OBSERVATIONS MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
1Hematologie biologique, Hôpital Saint Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France; 2Institut Universitaire d’hematologie, Hôpital Saint-Louis, Paris, France; 3Anatomie Pathologie, Hôpital Saint Louis, AP-HP, Paris, France; 4Institut Universitaire d’hématologie–Paris VII, Inserm U728, Paris, France; 5Hemato-oncology, Centre Hospitalier Universitaire (CHU) de l’Archet, Ni...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred o...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte
1Hospices Civils de Lyon and Université Lyon-1, Lyon, France; 2Hôpital Saint-Louis, Paris, France; 3Université Catholique de Louvain, Brussels, Belgium; 4Centre Hospitalier Général Henri Duffaut, Avignon, France; 5Hôpital V Provo, Roubaix, France; 6Hôpital André Mignot, Versailles, France; 7Centre Hospitalier, Brive, France; 8Groupe Hospitalier du Haut Leveque, Pessac, France; 9Centre Hospitali...
متن کامل